- Pressemitteilung BoxID 53703
Capsulution Nanosciences advances with drug delivery systems program
Further increase of capital strengthens development capacity
Over the next 12 months, the fresh capital will be used for the realization of supplementary preclinical trials with Capsulution's nanocapsules in order to validate their advantages in comparison to other common drug formulations in the area while transporting pharmaceutical agents within a living organism. The developers of Capsulution expect that the use of their nanocapsules will show a better performance in evaluating the bioavailability for poorly water soluble pharmaceuticals, resulting in a more effective and convenient therapy for the patient. Additional research is aiming for a targeted release of the medical substances within the organism in a time-controlled manner. The new effectiveness of the Capsulution nanocapsules could replace the common progress of multiple medication treatments especially for modern cancer therapy methods. For the international pharma clients, Capsulution's modern approach to encapsulation technology and innovative developments represents a unique opportunity to be a step ahead of the keen competition. A further part of the capital will be allocated to a joint development project in the medical device business aiming at combining Capsulution´s nano-encapsulation technology with medical products.
Capsulution develops innovative solutions for pharmaceutically active compounds - so-called drug delivery systems - to transport these safely and with increased effectiveness to the desired location of action in the human body. To achieve this, Capsulution applies its worldwide-patented nano-encapsulation technology – so called LBL-Technology®. Because of their minute size, their diverse functionalities as well as their highly reproducible production the capsules are suitable for a wide range of applications.
The latest shares have mainly been subscribed by Bernhard Penno, a private investor and entrepreneur from Germany. Another part of the shares has been subscribed as a follow-up investment by the KBB, a fund managed by BC Brandenburg Capital GmbH. "I'm fascinated by the strong benefit of Capsulution's products and their enormous market potential", said Bernhard Penno, the new private shareholder. "In addition, Capsulution's team is highly skilled and dedicated, thus ensuring a successful investment story to me."
For any further inquiries and information of Capsulution Nanoscience AG, please contact the mentioned contact persons.
About BC Brandenburg Capital GmbH
BC Brandenburg Capital is an early stage focussed venture capital company currently managing 5 funds. With over 10 years of market experience and an at present invested capital of more than EUR 40 million, BC accompanies over 40 enterprises as a partner and advisor. The main investment areas include Information and Communication Technology, Life Sciences, Microelectronics and Industrial Automation.
Über die Capsulution Pharma AG
Capsulution NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company implements its worldwide-patented LBL Technology®. Based on their minute size, their functionality and their highly reproducible production process, the tunable capsules can be used in a multitude of different applications. Accordingly, the precision-sized capsules can be made to function in a manner suited to the intended application, and can be given biochemical, electrical, optical and magnetic properties tailored to the individual customer. In order to meet customers’ needs for complete product solutions, Capsulution designated EBARA Corp. as the preferred developer, manufacturer and distributor for automated LBL units. In 2005, the renowned growth consultants Frost & Sullivan awarded the year’s “Product Differentiation Innovation Award” in the global nanobiotechnology market to Capsulution NanoScience AG, Berlin. The company received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications.
Weitere Pressemitteilungen dieses Herausgebers
- 22.02.2010 - Into the future with a stronger team
- 17.11.2008 - Capsulution and NanoDel merge their businesses
- 17.11.2008 - Capsulution und NanoDel schließen sich zu Capsulution Pharma zusammen